Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study found that exercise decreases the expression of 5αR1, thereby enhancing the PI3K/AKT signaling pathway in PCOS rats.

This study found that combining microneedle treatments with 5% minoxidil topical solution led to the greatest increase in hair density among Chinese men with androgenetic alopecia.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This study identified novel compounds as selective inhibitors of the type 1 isoenzyme of 5α-reductase, displaying promising potential for treating DHT-dependent disorders such as acne and androgenic alopecia.

Finasteride potentially treats hair loss by reducing DHT production.

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.

This study identified eight isoflavone derivatives as potential nonsteroidal inhibitors of rat 5α-reductase using a pharmacophore model in virtual screening.

This study found that combining fractional radiofrequency microneedling with 5% topical minoxidil improved hair count and thickness more than minoxidil alone in Chinese men with male pattern hair loss.

This study found that Cacumen platycladi extract significantly promoted hair growth and reduced dihydrotestosterone levels by inhibiting 5α-reductase activity in an androgen-sensitive mouse model.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study suggests that a mixture of 5‐ALA and iron ion significantly improved hair growth in mice, comparable to minoxidil, without promoting keratinocyte or fibroblast proliferation in vitro.

Androgen effects on hair follicles vary by skin area.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

This preliminary study suggests that baseline central serotonin turnover, indicated by CSF 5-HIAA levels, may influence treatment response to serotonin re-uptake inhibitors in women with trichotillomania.

This study found that women with lower 2D:4D ratios and fewer middle-phalangeal hairs reported more adverse side effects from oral contraceptives, suggesting these features may predict hormonal contraceptive side effects.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

This study found no significant association between selected gene variants and female pattern hair loss, suggesting these genes might not be involved in its development.

This study found that exposure to finasteride impaired spermatogenesis in male Xenopus laevis by affecting sex-specific feedback mechanisms in the hypothalamus–pituitary–gonad axis.